WilsonKG, ChochinovHM, SkirkoMG, et al.: Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage, 2007; 33:118–129.
2.
OstuzziG, MatchamF, DauchyS, et al.: Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev, 2018. [Epub ahead of print; doi: 10.1002/14651858.CD011006.pub3.]
3.
IrwinSA, IglewiczA, NelesenRA, et al.: Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial. J Palliat Med, 2013; 16:958–965.
4.
LeeEE, Della SelvaMP, LiuA, et al.: Ketamine as a novel treatment for major depressive disorder and bipolar depression: A systematic review and quantitative meta-analysis. Gen Hosp Psychiatry, 2015; 37:178–184.
5.
SchoeversRA, ChavesTV, BalukovaSM, et al.: Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry, 2016; 208:108–113.
6.
SussmanM, O'sullivanAK, ShahA, et al.: Economic burden of treatment-resistant depression on the U.S. Health Care System. J Manag Care Spec Pharm, 2019; 25:823–835.
7.
YanagiharaY, OhtaniM, KariyaS, et al.: Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos, 2003; 24:37–43.
8.
Stefanczyk-SapiehaL, OneschukD, DemasM: Intravenous ketamine “burst” for refractory depression in a patient with advanced cancer. J Palliat Med, 2008; 11:1268–1271.
9.
SextonJ, AtayeeRS, BrunerHC: Case report: Ketamine for pain and depression in advanced cancer. J Palliat Med, 2018; 21:1670–1673.
10.
McGirrA, BerlimMT, BondDJ, et al.: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med, 2015; 45:693–704.
11.
BermanRM, CappielloA, AnandA, et al.: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000; 47:351–354.
12.
NaughtonM, ClarkeG, O'LearyOF, et al.: A review of ketamine in affective disorders: Current evidence on clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord, 2014; 156:24–35.
13.
ZarateCAJr., SinghJB, CarlsonPJ, et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006; 68:856–864.
14.
MurrowJW, PerezAM, PillemerS, et al.: Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry, 2013; 74:250–256.
15.
LapidusKA, LevitchCF, PerezAM, et al.: A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry, 2014; 76:970–976.
16.
AndradeC: Intranasal drug delivery in neuropsychiatry: Focus on intranasal ketamine for refractory depression. J Clin Psychiatry, 2015; 76:e628–e631.
17.
IrwinSA, IglewiczA: Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med, 2010; 13:903–908.
18.
IglewiczA, MorrisonK, NelesenRA, et al.: Ketamine for the treatment of depression in patients receiving hospice care: A retrospective medical record review of thirty-one cases. Psychosomatics. 2015; 56:329–339.
JonesJL, MateusCF, MalcomRJ, et al.: Efficacy of ketamine in the treatment of substance use disorders: A systematic review. Front Psychiatry, 2018; 9:277.
21.
KimM, ChoS, LeeJH: The effects of long-term ketamine treatment on cognitive function in complex regional pain syndrome: A preliminary study. Pain Med, 2016; 17:1447–1451.
22.
ZhuW, DingZ, ZhangY, et al.: Risks associated with misuse of ketamine as a rapid-acting antidepressant. Neurosci Bull, 2016; 32:557–564.
23.
GutkinE, HussainSA, KimSH: Ketamine-induced biliary dilatation: From Hong Kong to New York. J Addict Med, 2012; 6:89–91.
24.
TrivediS, KumarR, TripathiAK, MehtaRK: A comparative study of dexmedetomidine and midazolam in reducing delirium caused by ketamine. J Clin Diagn Res, 2016; 10:UC01–4.
25.
JamkumarJ, FamJ, YeoEY, GaweGS: Ketamine and suicidal ideation in depression: Jumping the gun?. Pharmacol Res, 2015; 99:23–35.
